Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Vascular endothelial growth factor receptor (VEGFR) family consists of three primary receptor tyrosine kinases—VEGFR-1 (FLT1), VEGFR-2 (KDR), and VEGFR-3 (FLT4)—that are central regulators of angiogenesis, vasculogenesis, and lymphangiogenesis (UniProt: P17948, P35968, P35916). These receptors are activated by the binding of specific VEGF ligands, which induces receptor dimerization and aut}
Inhibition of receptor tyrosine kinase activity or blocking ligand-receptor binding to suppress pro-angiogenic and pro-lymphangiogenic signaling pathways.
12 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vascular endothelial growth factor receptor family (VEGFR) (VEGFR).